ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2360

Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis

Silvana Saavedra1, Karen Vergara 2, Claudia Hernandez 2, Pedro Zamorano 2, Annelise Goecke 2, Luis Toro 2 and FELIPE REYES 1, 1HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Chile, 2HOSPITAL CLINICO UNIVERSIDAD DE CHILE, Santiago, Region Metropolitana, Chile

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: disease-modifying antirheumatic drugs and rheumatoid arthritis (RA), interstitial lung disease

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: RA – Treatments Poster III: Safety and Outcomes

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is a common pulmonary manifestation of rheumatoid arthritis (RA) that may be related to the inflammatory process itself, to infectious complications, and/or to the therapy. Biological disease‐modifying antirheumatic drugs (bDMARD) have dramatically improved the outcome of RA, but an increasing number of reports have described  the potential lung toxicity of this group of drugs.

Methods: Retrospective cohort study using data from RA patients beneficiaries of the “Ley Ricarte Soto program”, at the Hospital Clínico Universidad de Chile, was conducted to assess ILD prevalence and exacerbations , among users of abatacept (ABA), rituximab (RTX), and anti-TNFα agents. Clinical findings and laboratory data were collected from medical records. The presence or progression of ILD on HRCT was evaluated by a rheumatologist, a pneumonologist and a radiologists who have expertise in assessing ILD, all part of the Rheumatic Lung Group at our Hospital.

Results: 126 RA patients were included; 85% female, mean (SD) age 55 (13.4) years, mean disease duration 11 (8.7 years). RA was seropositive in 108 patients (85.7%). DAS28 ESR was 6.1 (1.2) previously to initiate bDMARDs. A total of 30 patients (23.8%) had been previously diagnosed with ILD, most common patterns on HRCT were UIP (n=10[33%]) and bronchiolar abnormalities (n=4[13.3%]). Patients with as compared to without ILD at baseline were more frequently males (53 vs 15%, p < 0.05), had an older age (62.6 + 11.9 vs 55 + 13.4, p < 0.005), a higher positivity of anti-CCP (73 vs 47.6% p < 0.005) and a more frequent history of smoking (43 vs 21%, p < 0.005). The patients with a history of ILD were also, significantly more likely to receive ABA (n=24 [82.8] % versus n=35 [36.1%] without ILD; p < 0.001) and significantly less likely to receive anti-TNF therapy (n=3 [10.3%] versus n=57 [58.7 %] without ILD; p < 0.001). Only 6 patients received RTX, two of them with history of ILD. All patients with RA-associated ILD remained stable at 28 month follow-up. In the group of patients without a history of ILD, only one developed an organizing pneumonia that responded well to corticosteroids and was not related to the biological therapy.

Conclusion: Our data show that, in a real-world setting, there were no significant differences in the risk of complications between patients with or without a baseline history of ILD receiving different biologic agents. In our Cohort, bDMARDs were not associated with new ILD either. These data may be affected by the short follow-up window and the preference for the use of ABA, over anti-TNFα agents, as initial biological therapy in RA-ILD.


Disclosure: S. Saavedra, None; K. Vergara, None; C. Hernandez, None; P. Zamorano, None; A. Goecke, Roche, 5, 8, Abbvie, 5, 8, Novartis, 5, 8, Pfizer, 5, 8; L. Toro, None; F. REYES, None.

To cite this abstract in AMA style:

Saavedra S, Vergara K, Hernandez C, Zamorano P, Goecke A, Toro L, REYES F. Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/safety-of-biological-dmard-in-patients-with-interstitial-lung-disease-from-a-chilean-cohort-of-patients-with-rheumatoid-arthritis/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-of-biological-dmard-in-patients-with-interstitial-lung-disease-from-a-chilean-cohort-of-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences